



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 1672407

TO: Mary K Zeman
Art Unit: 1631
Location: REM-2D11&2C70
Serial Number: 09/846328

Wednesday, August 24, 2005

From: Beverly Shears
Location: Biotech-Chem Library
REM 1A54
Phone: 571-272-2528
beverly.shears@uspto.gov

Search Notes

Mary,

CAS search results also attached. Due to length, hit seqs. were not displayed in File Reg. To display the seq. of interest, search the RN and display the seq.

Beverly

L5 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 May 2002
ACCESSION NUMBER: 2002:354338 CAPLUS
DOCUMENT NUMBER: 136:364608
TITLE: The contribution of 700,000...

IT 298763-56-6, GenBank BF091353

FILE 'REGISTRY' ENTERED AT 09:12:25 ON 14 JUN 2005
=> s 298763-56-6/RN

L1 1 S 298763-56-6/RN

=> d seq

SEQ 1 ggctcgatca ctctgcgac gctgcgttag aacccatcg caggctgtt
251 ttgacagcat ttgaattc ctatgtacg tactta

Protein Sequence Searches – February 2005

All of the sequence databases on ABSS have recently been updated.

- Please note that the curators of the UniProt database have purged some temporary accession numbers from the most recent version of UniProt. These sequences have been assigned new permanent accession numbers. The new UniProt record may not contain the previous temporary accession number.
- If you encounter an accession number from an older search run against UniProt (results file extension .rup) that can no longer be found in the database, the permanent record with the new accession number can be found by searching the old accession number in the UniProt Protein Archive database (uniPARC) at:

<http://www.pir.uniprot.org/database/archive.shtml>

If you have any questions regarding this information or your results, please contact any STIC searcher.



162407

From: Zeman, Mary
 Sent: Friday, August 12, 2005 2:34 PM
 To: STIC-Biotech/ChemLib
 Subject: Sequence search 09/846328

Peptide search:

Please search amino acids 2-25 of SEQ ID NO: 1 of 09/846328
 please search all peptide files, including interference and REGISTRY
 paper printout please

Thank you, Mary Z

Mary K. Zeman
 Primary Examiner, 1631
 571-272-0723
 Remsen 2D61
 MAILBOX: REM 2C70
 mary.zeman@uspto.gov

CRPE

AA 26

My

STAFF USE ONLY

Searcher: _____
 Searcher Phone: 2-
 Date Searcher Picked Up: 8/12/05
 Date Completed: 8/12/05
 Searcher Prep/Rev. Time: _____
 Online Time: _____

Type of Search

NA#: _____ AA#: _____
 Interference: _____ SPDI: _____
 S/L: _____ Oligomer: _____
 Encode/Transl: _____
 Structure#: _____ Text: _____
 Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
 DIALOG: _____
 QUESTEL/ORBIT: _____
 LEXIS/NEXIS: _____
 SEQUENCE SYSTEM: _____
 WWW/Internet: _____
 Other(Specify): _____

Date completed: _____
 Searcher: Beverly e 2528

Terminal time: _____

Elapsed time: _____

CPU time: _____

Total time: _____

Number of Searches: _____

Number of Databases: _____

Search Site

____ STIC
 ____ CM-1
 ____ Pre-S

Type of Search

____ N.A. Sequence
 ____ A.A. Sequence
 ____ Structure
 ____ Bibliographic

Vendors

____ IG
 ✓ STN
 ____ Dialog
 ____ APS
 ____ Geninfo
 ____ SDC
 ____ DARC/Questel
 ✓ Other CGN

Zeman, M.
091846328

09/846328

FILE 'REGISTRY' ENTERED AT 14:31:09 ON 23 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2005 HIGHEST RN 861291-85-2
DICTIONARY FILE UPDATES: 22 AUG 2005 HIGHEST RN 861291-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L1 874 DAHKSEVAHRFKDLGEENFKALVL/SQSP

FILE 'CAPLUS' ENTERED AT 14:32:01 ON 23 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Aug 2005 VOL 143 ISS 9
FILE LAST UPDATED: 22 Aug 2005 (20050822/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

Searcher : Shears 571-272-2528

substance identification.

L2 148 SEA ABB=ON PLU=ON L1
 L3 4 SEA ABB=ON PLU=ON L2 AND (BIOMARKER OR (BIO OR BIOL?) (W)M
 ARKER)
 L4 20 SEA ABB=ON PLU=ON L2 AND (INDICAT? OR DETERM? OR DETECT?
 OR DET## OR SCREEN? OR DIAGNOS?) (S) (DISEAS? OR DISORDER)
 L5 21 SEA ABB=ON PLU=ON L3 OR L4

L5 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 13 May 2005

ACCESSION NUMBER: 2005:409130 CAPLUS
 DOCUMENT NUMBER: 142:458903

TITLE: Sequences of KDR and VEGF/KDR binding peptides,
 peptide dimers, and multimeric complexes and their
 use in diagnosis and therapy

INVENTOR(S): Sato, Aaron K.; Sexton, Daniel J.; Dransfield,
 Daniel T.; Ladner, Robert C.; Arbogast,
 Christophe; Bussat, Philippe; Fan, Hong; Khurana,
 Sudha; Linder, Karen E.; Marinelli, Edmund R.;
 Nanjappan, Palaniappa; Nunn, Adrian D.; Pillai,
 Radhakrishna; Pochon, Sibylle; Ramalingam,
 Kondareddiar; Srivastava, Ajay; Song, Bo;
 Swenson, Rolf E.; Von Wronski, Mathew A.

PATENT ASSIGNEE(S): Dyax Corporation, USA; Bracco International B. V.

SOURCE: U.S. Pat. Appl. Publ., 373 pp., Cont.-in-part of
 U.S. Ser. No. 382,082, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005100963	A1	20050512	US 2003-661156	20030911
WO 2003074005	A2	20030912	WO 2003-US6731	20030303
WO 2003074005	C1	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-360851P	P 20020301
			US 2003-440411P	P 20030115
			US 2003-382082	B2 20030303
			WO 2003-US6731	A2 20030303

OTHER SOURCE(S): MARPAT 142:458903

AB The present invention provides polypeptides, peptide dimer, and

multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 μM), and dimer and multimeric constructs comprising these polypeptides.

IT 851737-28-5 851737-29-6

RL: PRP (Properties)

(unclaimed protein sequence; sequences of KDR and VEGF/KDR binding peptides, peptide dimers, and multimeric complexes and their use in diagnosis and therapy)

L5 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 11 Feb 2005

ACCESSION NUMBER: 2005:121193 CAPLUS

DOCUMENT NUMBER: 142:214836

TITLE: Biomarkers of cyclin-dependent kinase modulation in cancer therapy

INVENTOR(S): Li, Martha; Rupnow, Brent A.; Webster, Kevin R.; Jackson, Donald G.; Wong, Tai W.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012875	A2	20050210	WO 2004-US24424	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2003-490890P	P 20030729

AB Biomarkers having expression patterns that correlate with a response of cells to treatment with one or more cdk modulating agents, and uses thereof. Transcription profiling was used to identify the biomarkers. Specifically, transcription profiling of the effect of a certain cdk2 inhibitor (BMS 387032 0.5 L-tartaric acid salt) on peripheral blood mononuclear cells was first performed. Gene chips were used to quantitate the levels of gene expression on a large-scale with Affymetrix human gene chips HG-U95A, B, and C. Next, profiling of a cdk2 inhibitor-treated tumor cell line A28780 at multiple doses and time points was performed to establish a correlation of tumor site response with peripheral blood biomarkers. In order to establish the mol. target-specificity of the potential biomarkers, tumor cell line A2780 treated

with anti-cdk2 oligonucleotides was also profiles. Overlapping gene expression changes were selected for further evaluation in human ovarian carcinoma xenograft A2780 that were treated with the cdk2 inhibitor. The selected **biomarkers** were subjected to real-time PCR anal. in order to verify the observed changes from the gene chip anal. The **biomarker** comprising GenBank accession number W28729 was discovered to have the most consistent and robust regulation in response to cdk inhibition. Provided are methods for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer that comprises administering an agent that modulates cdk activity.

IT 841330-10-7

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses) (amino acid sequence; **biomarkers** of cyclin-dependent kinase modulation in cancer therapy)

L5 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 21 Jan 2005

ACCESSION NUMBER: 2005:58367 CAPLUS

DOCUMENT NUMBER: 142:152638

TITLE: Aging-related genes identified in growth hormone receptor/binding protein (GHR/BP) gene-disrupted mouse model, corresponding human genes, and diagnosis and treatment methods

INVENTOR(S): Kopchick, John J.; Riders, Markus; Coschigano, Karen T.; Gosney, Elahu S.

PATENT ASSIGNEE(S): Ohio University, USA

SOURCE: PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005668	A2	20050120	WO 2004-US21944	20040708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-485222B P 20030708

AB Mouse genes differentially expressed in comparisons of gene expression in growth hormone receptor/binding protein (GHR/BP) gene-disrupted mouse livers and normal mouse livers have been identified, as have corresponding human genes and proteins. The human mols., or antagonists thereof, may be used for protection against faster-than-normal biol. aging, or to achieve slower-than-normal biol. aging. The human mols. may also be used as markers of biol. aging, to

retard biol. aging, or to treat age-related diseases.
 IT 479944-61-1 479953-99-6, GenBank AAN17825
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; aging-related genes identified in growth
 hormone receptor/binding protein (GHR/BP) gene-disrupted mouse
 model, corresponding human genes, and diagnosis and treatment
 methods)

L5 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 11 Nov 2004
 ACCESSION NUMBER: 2004:956980 CAPLUS
 DOCUMENT NUMBER: 141:406785
 TITLE: Polymorphisms in known genes associated with human
 disease and methods of their detection and uses
 INVENTOR(S): Venter, J. Craig; Zhang, Jinghui N.; Liu,
 Xiangjun; Rowe, William; Cravchik, Anibal; Kalush,
 Francis; Naik, Ashwinikumar; Subramanian,
 Gangadharan; Woodage, Trevor
 PATENT ASSIGNEE(S): Applera Corporation, USA
 SOURCE: U.S., 24 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6812339 B1	-----	20041102	US 2001-XA949016 US 2000-PV231498 US 2000-PV237768 US 2000-PV241755 US 2001-949016	20010910 20000908 20001003 20001020. 20010910
PRIORITY APPLN. INFO.:				

AB The present invention is based on the discovery of novel polymorphisms (SNPs) and previously unknown haplotypes in genes known in the art to contribute to human disease. Such polymorphisms can lead to a variety of disorders that are mediated/modulated by a variant human disease associated protein. The shotgun sequencing method was during to sequence and assembly the human genome. During the sequencing phase, DNA samples from six individuals of various racial backgrounds (Caucasian, Hispanic, Chinese, and Negro) were sequenced to various extents and the sequence fragments were assembled to obtain an assembled consensus genomic sequence for human. Since DNA was sampled from six individuals, and each individual represents two sets of chromosomes, in addition to the consensus, genetic variation was found in the assemblies. The genomic assembly and identified sequence variation was then compared to publicly known genes involved in human disease. Regions of the assemblies that represent 5871 corresponding genes were selected and 189,399 SNP variations are provided. The present invention provides reagents used for detecting and expressing the variant nucleic acid/protein sequence as well as methods of identifying and using these variants. [This abstract record is one of thirty records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L5 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 21 Oct 2004
 ACCESSION NUMBER: 2004:872879 CAPLUS

09/846328

DOCUMENT NUMBER: 141:348152
TITLE: Changes in protein profiles in colorectal cancer tissues and their use in diagnosis
INVENTOR(S): Raskov, Hans Henrik; Albrethsen, Jacob;
Gammeltoft, Steen; Bogebo, Rikke Maria
PATENT ASSIGNEE(S): Colotech A/S, Den.
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004090550	A2	20041021	WO 2004-DK263	20040407
WO 2004090550	A3	20050106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			DK 2003-541	A 20030408
			DK 2003-1085	A 20030716

AB Proteins showing changes in levels in colorectal cancer are identified. Anal. of the levels of several of these proteins may be used in the **diagnosis** of the **disease**. The markers have been identified by assaying a number of tissue and serum samples from healthy individuals and persons diagnosed with colorectal cancer by means of protein chip technol. using mass spectrometry. Differential expression pattern of these markers are indicative of a person having colorectal cancer patient. The diagnosis is based on comparing at least one intensity value, obtained using the method, to a reference value.

IT 774620-03-0

RL: PRP (Properties)

(unclaimed protein sequence; changes in protein profiles in colorectal cancer tissues and their use in diagnosis)

L5 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 08 Oct 2004

ACCESSION NUMBER: 2004:825035 CAPLUS

DOCUMENT NUMBER: 141:308582

TITLE: Proteomic analysis of biological fluids, particularly amniotic fluid and maternal serum, for diagnosing maternal/fetal conditions

INVENTOR(S): Rosenfeld, Ron; Nagalla, Sri; Gravett, Mike

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp.

CODEN: USXXCO

Searcher : Shears 571-272-2528

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004197930	A1	20041007	US 2003-400005	20030325
WO 2004088324	A2	20041014	WO 2004-US8954	20040323
WO 2004088324	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-400005 A 20030325

AB The present invention provides non-invasive and sensitive methods for the early diagnosis, prognosis, and monitoring of pathol. fetal/maternal conditions, by proteomic anal. of biol. fluids. The invention concerns the identification of proteomes of biol. fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns the identification of the proteome of amniotic fluid (multiple proteins representing the composition of amniotic fluid) and the correlation of characteristic changes in the normal proteome with various pathol. maternal/fetal conditions, such as intra-amniotic infection, or chromosomal defects.

IT 444951-52-4, Alloalbumin Venezia (human gene ALB)
 445052-67-5, Albumin (human gene ALB)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; proteomic anal. of biol. fluids, particularly amniotic fluid and maternal serum, for diagnosing maternal/fetal conditions)

L5 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 06 Aug 2004

ACCESSION NUMBER: 2004:634089 CAPLUS
 DOCUMENT NUMBER: 141:167846
 TITLE: Binding peptides for the KDR receptor and vascular endothelial growth factor/KDR complex and their use in diagnosis, therapy, and imaging of angiogenesis-related disorders
 INVENTOR(S): Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladner, Robert C.; Arbogast, Christophe; Bussat, Philippe; Fan, Hong; Khurana, Sudha; Linder, Karen E.; Marinelli, Edmund R.; Nanjappan, Palaniappa; Nunn, Adrian; Pillai,

PATENT ASSIGNEE(S) : Radhakrishna; Pochon, Sibylle; Ramalingam,
 Kondareddiar; Shrivastava, Ajay; Song, Bo;
 Swenson, Rolf E.; Von Wronski, Mathew A.
 Dyax Corp., USA; Bracco International B.V.

SOURCE: PCT Int. Appl., 470 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065621	A1	20040805	WO 2003-US28787	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003074005	A2	20030912	WO 2003-US6731	20030303
WO 2003074005	C1	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-360851P	P 20020301
			US 2003-440411P	P 20030115
			US 2003-382082	A2 20030303
			WO 2003-US6731	A2 20030303

OTHER SOURCE(S) : MARPAT 141:167846

AB The present invention provides peptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR receptor or vascular endothelial growth factor (VEGF)/KDR complex, which have a variety of uses wherever treating, detecting, isolating, or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated peptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD < 1 μ M), and dimer and multimeric constructs comprising these polypeptides. The involvement of VEGF and KDR in angiogenesis makes the binding peptides particularly useful for imaging important sites of angiogenesis, e.g., neoplastic tumors, for targeting substances, e.g., therapeutics,

including radiotherapeutics, to such sites, and for treating certain disease states, including those associated with inappropriate angiogenesis.

IT 735863-67-9 735863-68-0

RL: PRP (Properties)

(unclaimed sequence; binding peptides for the KDR receptor and vascular endothelial growth factor/KDR complex and their use in diagnosis, therapy, and imaging of angiogenesis-related disorders)

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 14 May 2004

ACCESSION NUMBER: 2004:392574 CAPLUS

DOCUMENT NUMBER: 140:405466

TITLE: Differentially expressed nucleic acids and their encoded proteins useful for the diagnosis and treatment of immune-related diseases

INVENTOR(S): Aggarwal, Sudeepa; Clark, Hilary; Gurney, Austin L.; Schoenfeld, Jill; Williams, P. Mickey; Wood, William I.; Wu, Thomas D.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 3009 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039956	A2	20040513	WO 2003-US34381	20031028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2503330	AA	20040513	CA 2003-2503330	20031028
PRIORITY APPLN. INFO.:			US 2002-422472B	P 20021029
			WO 2003-US34381	W 20031028

AB The present invention relates to compns. containing novel proteins and methods of using those compns. for the diagnosis and treatment of immune-related diseases. Various polypeptides of the present invention are significantly differentially expressed in isolated CD45RO cells activated by anti-CD3/anti-CD28 as compared to isolated resting CD45RO cells, isolated resting CD45RA cell, and isolated CD45RA cells activated by anti-CD3/anti-CD28 antibodies.

IT 688832-62-4

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; differentially expressed nucleic acids and their encoded proteins useful for the diagnosis and treatment of immune-related diseases)

L5 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 26 Mar 2004
 ACCESSION NUMBER: 2004:250754 CAPLUS
 DOCUMENT NUMBER: 140:282451
 TITLE: Human protein and cDNA sequences for diagnostics and therapeutics
 INVENTOR(S): Schmidt, Jeanette P.; Wright, Rachel J.; Bruns, Christopher M.; Marjanovic, Mirjana M.; Shen, Fan; Harthshorne, Toinette A.; Suchorolski, Martin T.; Altus, Christina M.; Pitts, Steven J.; Elder, Linda V.; Mooney, Elizabeth M.; Delegeane, Angelo M.; Panesar, Iqbal S.; Banville, Steven C.; Reddy, Thirupathi P.; Stevens, Kristian A.; Blanchard, John L.; Panzer, Scott R.; Wang, Xinhao; Au, Alan P.; Gerstlin, Edward H., Jr.; Peralta, Careyna H.; Anderson, Scott B.; Rioux, Pierre; Shen, Edward J.; Wu, Mingham C.; Stuve, Laura L.; Lagace, Robert E.; Spiro, Peter A.; Stewart, Elizabeth A.; Wingrove, James; Vitt, Ursula A.; Kirton, Edward S.; Xu, Yuming; Kwong, Mary; Policky, Jennifer L.; Hurwitz, Bonnie L.; Ma, Yan; Jackson, Jennifer L.; Gietzen, Darryl; Patury, Srikanth; Shi, Xiaobing; Suarez, Charlyn J.
 PATENT ASSIGNEE(S): Incyte Corporation, USA
 SOURCE: PCT Int. Appl., 190 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004023973	A2	20040325	WO 2003-US28227	20030912
WO 2004023973	A3	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-410259P	P 20020912
			US 2002-410260P	P 20020912

AB The present invention provides 2722 human cDNA sequences for diagnostics and therapeutics (dithp) and the polypeptides (DITHP) encoded by dithp. The invention also provides for the use of dithp,

or complements, oligonucleotides, or fragments thereof in diagnostic assays. The invention further provides for vectors and host cells containing dithp for the expression of DITHP. The invention addnl. provides for the use of isolated and purified DITHP to induce antibodies and to screen libraries of compds. and the use of anti-DITHP antibodies in diagnostic assays. Also provided are microarrays containing dithp and methods of use.

IT 674869-07-9 674869-08-0 674869-09-1

674869-10-4

RL: ANT (Analyte); BSU (Biological study; unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; human protein and cDNA sequences for diagnostics and therapeutics)

L5 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 03 Feb 2004

ACCESSION NUMBER: 2004:85984 CAPLUS

DOCUMENT NUMBER: 140:194432

TITLE: Human prostate cancer marker genes associated with various metastatic stages identified by gene profiling, and related compositions, kits, and methods for diagnosis, prognosis and therapy

INVENTOR(S): Schlegel, Robert; Endege, Wilson O.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 131 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
PRIORITY APPLN. INFO.:			US 2001-297285P	P 20010611
			US 2002-166883	A 20020611

AB The invention relates to compns., kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer. In particular, three sets of the marker genes set, corresponding to 11617 GenBank Accession Nos. (only 2168 new submissions) and 15 SEQ IDs, are identified by transcription profiling using RNA derived from clin. samples, that were expressed at least 2-fold or greater than the normal controls. Using TNM staging approach, these markers are divided to three groups, ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the liver (M stage); ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the bone (M stage); and ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the lymph nodes (N stage and/or M stage). The invention also relates to a kit for assessing the specific type of metastatic prostate cancer, e.g., cancer that has metastasized to the liver, bone or lymph nodes. [This abstract record is one of three records for this document necessitated

by the large number of index entries required to fully index the document and publication system constraints.].

IT 444951-52-4, Alloalbumin Venezia (human gene ALB)
 445052-67-5, Albumin (human gene ALB) 487511-25-1
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; human prostate cancer marker genes associated with various metastatic stages identified by gene profiling, and related compns., kits, and methods for diagnosis, prognosis and therapy)

L5 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 16 Jan 2004
 ACCESSION NUMBER: 2004:39697 CAPLUS
 DOCUMENT NUMBER: 140:123703
 TITLE: Human prostate cancer marker genes associated with various metastatic stages identified by gene profiling, and related compositions, kits, and methods for diagnosis, prognosis and therapy
 INVENTOR(S): Schlegel, Robert; Endege, Wilson O.
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 131 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
PRIORITY APPLN. INFO.:			US 2001-297285P	P 20010611
			US 2002-166883	A 20020611

AB The invention relates to compns., kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer. In particular, three sets of the marker genes set, corresponding to 11617 GenBank Accession Nos. (only 2168 new submissions) and 15 SEQ IDs, are identified by transcription profiling using RNA derived from clin. samples, that were expressed at least 2-fold or greater than the normal controls. Using TNM staging approach, these markers are divided to three groups, ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the liver (M stage); ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the bone (M stage); and ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the lymph nodes (N stage and/or M stage). The invention also relates to a kit for assessing the specific type of metastatic prostate cancer; e.g., cancer that has metastasized to the liver, bone or lymph nodes. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document

and publication system constraints.].
 IT 487505-60-2, Protein (human 585-amino acid)
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; human prostate cancer marker genes associated
 with various metastatic stages identified by gene profiling, and
 related compns., kits, and methods for diagnosis, prognosis and
 therapy)

L5 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 07 Jan 2004
 ACCESSION NUMBER: 2004:11083 CAPLUS
 DOCUMENT NUMBER: 140:71531
 TITLE: Genes expressed in C3A liver cell cultures treated
 with steroids
 INVENTOR(S): Furness, L. Michael; Buchbinder, Jenny L.
 PATENT ASSIGNEE(S): Incyte Corporation, USA
 SOURCE: U.S., 141 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6673549	B1	20040106	US 2001-976594	20011012
PRIORITY APPLN. INFO.:			US 2000-240409P	P 20001012

AB The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in human C3A liver cell cultures treated with steroids or synthetic steroid analogs. The cDNAs may be used entirely or in part to detect metabolic and toxicol. responses to treatment with steroids and steroid antagonists, and to diagnose, to stage, to treat, or to monitor the treatment of a subject with an steroid responsive disorder.

IT 641663-89-0
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN
 (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST
 (Analytical study); BIOL (Biological study); USES (Uses)
 (amino acid sequence; genes expressed in C3A liver cell cultures
 treated with steroids)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L5 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 24 Oct 2003
 ACCESSION NUMBER: 2003:837371 CAPLUS
 DOCUMENT NUMBER: 139:333132
 TITLE: Targets for therapeutic intervention identified in
 the human mitochondrial proteome
 INVENTOR(S): Ghosh, Soumitra S.; Fahy, Eoin D.; Zhang, Bing;
 Gibson, Bradford W.; Taylor, Steven W.; Glenn,
 Gary M.; Warnock, Dale E.
 PATENT ASSIGNEE(S): Mitokor, USA; The Buck Institute for Age Research
 SOURCE: PCT Int. Appl., 180 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087768	A2	20031023	WO 2003-US10870	20030404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004101874	A1	20040527	US 2003-408765	20030404
PRIORITY APPLN. INFO.:			US 2002-372843P	P 20020412
			US 2002-389987P	P 20020617
			US 2002-412418P	P 20020920

AB Mitochondrial targets for drug **screening** assays and for therapeutic intervention in the treatment of **diseases** associated with altered mitochondrial function are provided. Complete amino acid sequences are provided for 3025 polypeptides that comprise the human heart mitochondrial proteome, using fractionated proteins derived from highly purified mitochondrial preps., to identify previously unrecognized mitochondrial mol. components. Oxidative post-translational modification of tryptophan residues to N-formylkynurenine in cardiac mitochondrial proteins is also demonstrated by mass spectrometry.

IT 612101-68-5 612102-19-9

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence; targets for therapeutic intervention identified in the human mitochondrial proteome)

L5 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 26 Sep 2003

ACCESSION NUMBER: 2003:757212 CAPLUS

DOCUMENT NUMBER: 139:273225

TITLE: Tests for the rapid evaluation of ischemic states, and kits

INVENTOR(S): Bar-Or, David; Lau, Edward; Winkler, James V.; Fagan, Gary; Wayment, Hollie

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 48 pp., Cont.-in-parts of U. S. Ser. No. 232,341.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003180820	A1	20030925	US 2002-319263	20021213
US 6461875	B1	20021008	US 1998-165926	19981002
US 6475743	B1	20021105	US 1998-165961	19981002
US 6492179	B1	20021210	US 1998-165581	19981002
WO 2000020840	A1	20000413	WO 1999-US22905	19991001
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003017506	A1	20030123	US 2002-232341	20020830
US 2005142613	A1	20050630	US 2005-33766	20050112
PRIORITY APPLN. INFO.:				
US 1998-102738P P 19981002				
US 1998-165581 W 19981002				
US 1998-165926 W 19981002				
US 1998-165961 A3 19981002				
US 1999-115392P P 19990111				
WO 1999-US22905 W 19991001				
US 2001-806247 A2 20010327				
US 2001-820416 A2 20010329				
US 2002-232341 A2 20020830				
US 2002-319263 A1 20021213				

AB The present invention relates to rapid methods for the detection of ischemic states and to kits for use in such methods. Provided for is a rapid method of testing for and quantifying ischemia based upon methods of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating albumin, anal. and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of endogenous copper in a purified albumin sample and use of an immunol. assay specific to the altered form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the detection and measurement of an ischemic event by measuring albumin N-terminal derivs. that arise following an ischemic event, including truncated albumin species lacking one to four N-terminal amino acids or albumin with an acetylated N-terminal Asp residue. Patient blood serum samples were reacted with CoCl₂ and then with dithiothreitol before addition of NaCl and A470 spectroscopy measurements were taken. The ischemia test was pos. if the optical d. was greater than or equal to 0.400 OD.

IT 606155-61-7

RL: PRP (Properties)

(unclaimed protein sequence; tests for the rapid evaluation of ischemic states, and kits)

L5 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 14 Sep 2003

ACCESSION NUMBER: 2003:719271 CAPLUS

DOCUMENT NUMBER: 139:265740

TITLE: KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

INVENTOR(S): Sato, Aaron K.; Sexton, Daniel J.; Ladner, Robert C.; Dransfield, Daniel T.; Swenson, Rolf E.; Marinelli, Edmund R.; Ramalingam, Kondareddiar; Nunn, Adrian D.; Von Wronski, Mathew A.; Srivastava, Ajay; Pochon, Sibylle; Bussat, Philippe; Arbogast, Christophe; Pillai, Radhakrishna; Fan, Hong; Linder, Karen E.; Song, Bo; Nanjappan, Palaniappa

PATENT ASSIGNEE(S): Dyax Corp., USA; Bracco International B.V.; et al.

SOURCE: PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074005	A2	20030912	WO 2003-US6731	20030303
WO 2003074005	C1	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477836	AA	20030912	CA 2003-2477836	20030303
WO 2004065621	A1	20040805	WO 2003-US28787	20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005100963	A1	20050512	US 2003-661156	20030911
PRIORITY APPLN. INFO.:			US 2002-360851P	P 20020301

US 2003-440411P	P 20030115
US 2003-382082	A2 20030303
WO 2003-US6731	W 20030303

OTHER SOURCE(S): MARPAT 139:265740

AB The present invention relates to polypeptides useful for detecting and targeting primary receptors on endothelial cells for VEGF, i.e., VEGF receptor 2, also known as kinase domain region (KDR) and fetal liver kinase-1 (Flk-1), and for imaging and targeting complexes formed by VEGF and KDR. The involvement of VEGF and KDR in angiogenesis makes the VEGF/KDR and KDR binding polypeptides of the present invention particularly useful for imaging important sites of angiogenesis, e.g., neoplastic tumors, for targeting substances, e.g., therapeutics, including radiotherapeutics, to such sites, and for treating certain disease states, including those associated with inappropriate angiogenesis. Disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 μM).

IT 597590-53-9 597590-54-0

RL: PRP (Properties)
 (unclaimed sequence; KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy)

L5 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 13 Jun 2003

ACCESSION NUMBER: 2003:454906 CAPLUS

DOCUMENT NUMBER: 139:18402

TITLE: Genes differentially expressed in treated human C3A liver cell cultures and useful for **diagnosis** and treatment of liver **disorders**

INVENTOR(S): Kaser, Matthew R.

PATENT ASSIGNEE(S): Incyte Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2003108871	A1	20030612	US 2001-919039	20010730
US 6727066	B2	20040427	-----	-----
PRIORITY APPLN. INFO.:			US 2000-222113P	P 20000728

AB The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in treated human C3A liver cell cultures and which may be used entirely or in part to **diagnose**, to stage, to treat, or to monitor the progression or treatment of liver **disorders** such as hyperlipidemia, type II diabetes, and tumors of the liver. The human C3A cell line is a clonal derivative of HepG2/C3 (hepatoma cell line), which was selected for strong contact inhibition of growth. Gene expression changes in C3A cells in response to clofibrate, fenofibrate, captopril, enalapril, dexamethasone, diethylstilbestrol, 3-methylcholanthrene, LY294002, and insulin plus LY294002 are provided.

IT 536784-18-6P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; genes differentially expressed in treated human C3A liver cell cultures and useful for diagnosis and treatment of liver disorders)

L5 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 01 Nov 2002

ACCESSION NUMBER: 2002:833546 CAPLUS

DOCUMENT NUMBER: 137:334906

TITLE: Serum albumin biopolymer marker indicative of insulin resistance having a molecular weight of 2937 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161177	A1	20021031	US 2001-846329	20010430
US 6620786	B2	20030916		
WO 2002088742	A2	20021107	WO 2002-CA613	20020426
WO 2002088742	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-846329 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DAHKSEVAHREFKDLGEENFKALVLIA and characterized as a serum albumin having a mol. weight of 2937 daltons was found. This marker is indicative of insulin resistance.

IT 473546-58-6

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (serum albumin biopolymer marker of 2937 daltons indicative of insulin resistance)

L5 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 01 Nov 2002

ACCESSION NUMBER: 2002:833428 CAPLUS

DOCUMENT NUMBER: 137:333522

TITLE: Biopolymer marker **indicative of disease** state having a molecular weight of 2753 daltons

INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy

PATENT ASSIGNEE(S): Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160531	A1	20021031	US 2001-846328	20010430
WO 2002088710	A2	20021107	WO 2002-CA626	20020429
WO 2002088710	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-846328	A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular **disease** state; thereby enabling a **diagnostician** to gain the ability to characterize either the presence or absence of said at least one **disease** state relative to recognition of the presence and/or the absence of said biopolymer.

IT 98420-25-8

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (biopolymer marker **indicative of disease** state having a mol. weight of 2753 daltons)

L5 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 01 Nov 2002
 ACCESSION NUMBER: 2002:833395 CAPLUS
 DOCUMENT NUMBER: 137:348834
 TITLE: Process for diagnosis of physiological conditions by characterization of proteomic materials
 INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 25 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160420	A1	20021031	US 2001-846330	20010430
CA 2445554	AA	20021107	CA 2002-2445554	20020429
WO 2002088744	A2	20021107	WO 2002-CA623	20020429
WO 2002088744	A3	20030918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1384082	A2	20040128	EP 2002-766587	20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-846330	A 20010430
			WO 2002-CA623	W 20020429

AB The present invention discloses the use of proteomic investigation as a diagnostic tool; and particularly teaches the use of proteomic investigative techniques and methodol. to determine a proteomic basis for the development and progression of abnormal physiol. conditions and the development and characterization of risk assessment, diagnostic and therapeutic means and methodologies. Serum samples from patients suffering from a variety of diseases in Syndrome X were analyzed by SELDI mass spectrometry using the Ciphergen PROTEINCHIP system to discern disease markers.

IT 474451-19-9 474451-20-2
 RL: PRP (Properties)
 (unclaimed sequence; process for diagnosis of physiol. conditions by characterization of proteomic materials)

L5 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 01 Mar 2002
 ACCESSION NUMBER: 2002:157817 CAPLUS
 DOCUMENT NUMBER: 136:215418
 TITLE: B lymphocyte stimulator protein-binding polypeptides for BLyS detection and purification
 INVENTOR(S): Beltzer, James P.; Potter, M. Daniel; Fleming,

PATENT ASSIGNEE(S): Tony J.; Ladner, Robert Charles
 SOURCE: Dyax Corp., USA
 PCT Int. Appl., 269 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016412	A2	20020228	WO 2001-US25891	20010817
WO 2002016412	A3	20030626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2418006	AA	20020228	CA 2001-2418006	20010817
AU 2001085066	A5	20020304	AU 2001-85066	20010817
EP 1339746	A2	20030903	EP 2001-964181	20010817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003194743	A1	20031016	US 2001-932322	20010817
JP 2004532604	T2	20041028	JP 2002-521507	20010817
PRIORITY APPLN. INFO.: US 2000-226489P P 20000818				
WO 2001-US25891 W 20010817				

OTHER SOURCE(S): MARPAT 136:215418

AB Binding polypeptides comprising specific amino acid sequences are disclosed that bind B Lymphocyte Stimulator (BlyS) protein or BlyS-like polypeptides. The binding polypeptides can be used in methods of the invention for detecting or isolating BlyS protein or BlyS-like polypeptides in solns. or mixts., such as blood, tissue samples, or conditioned media.

IT 402550-28-1

RL: PRP (Properties)
 (unclaimed protein sequence; b lymphocyte stimulator protein-binding polypeptides for BlyS detection and purification)

L5 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2005 ACS on STN
 ED Entered STN: 01 Mar 2002
 ACCESSION NUMBER: 2002:157816 CAPLUS
 DOCUMENT NUMBER: 136:215417
 TITLE: B lymphocyte stimulator protein (BlyS) binding polypeptides for diagnosis and treatment of immunological disorders
 INVENTOR(S): Beltzer, James P.; Potter, Daniel M.; Fleming, Tony L.; Rosen, Craig A.
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 387 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016411	A2	20020228	WO 2001-US25850	20010817
WO 2002016411	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088301	A5	20020304	AU 2001-88301	20010817
US 2003091565	A1	20030515	US 2001-932613	20010817
PRIORITY APPLN. INFO.: US 2000-226700P P 20000818				
WO 2001-US25850 W 20010817				

AB Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The present invention further relates to methods and compns. for preventing, treating or ameliorating a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate BLyS function or BLyS receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more BLyS binding polypeptides or fragments or variants thereof, that specifically bind to BLyS. The aberrant BLyS or BLyS receptor expression conditions include immunol. diseases, autoimmune diseases, immunodeficiency, lupus, glomerular nephritis, rheumatoid arthritis, multiple sclerosis, hypogammaglobulinemia or hypergammaglobulinemia, graft vs. host disease, cancer, infectious disease, leukemia, lymphoma, hematopoietic cell proliferative disease, chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, T cell proliferative disease, acute myelogenous leukemia, etc.

IT 402550-23-6
 RL: PRP (Properties)
 (unclaimed protein sequence; b lymphocyte stimulator protein (BLyS) binding polypeptides for diagnosis and treatment of immunol. disorders)

E1 THROUGH E30 ASSIGNED

FILE 'REGISTRY' ENTERED AT 14:37:54 ON 23 AUG 2005
 L6 30 SEA FILE=REGISTRY ABB=ON PLU=ON (444951-52-4/B1 OR
 445052-67-5/B1 OR 402550-23-6/B1 OR 402550-28-1/B1 OR
 473546-58-6/B1 OR 474451-19-9/B1 OR 474451-20-2/B1 OR
 479944-61-1/B1 OR 479953-99-6/B1 OR 487505-60-2/B1 OR
 487511-25-1/B1 OR 536784-18-6/B1 OR 597590-53-9/B1 OR

09/846328

597590-54-0/BI OR 606155-61-7/BI OR 612101-68-5/BI OR
612102-19-9/BI OR 641663-89-0/BI OR 674869-07-9/BI OR
674869-08-0/BI OR 674869-09-1/BI OR 674869-10-4/BI OR
688832-62-4/BI OR 735863-67-9/BI OR 735863-68-0/BI OR
774620-03-0/BI OR 841330-10-7/BI OR 851737-28-5/BI OR
851737-29-6/BI OR 98420-25-8/BI)

L7 30 L1 AND L6

L7 ANSWER 1 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **851737-29-6** REGISTRY
CN 502: PN: US20050100963 SEQID: 501 unclaimed protein (9CI) (CA INDEX
NAME)
SQL 690
MF Unspecified
CI MAN

REFERENCE 1: 142:458903

L7 ANSWER 2 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **851737-28-5** REGISTRY
CN 501: PN: US20050100963 SEQID: 500 unclaimed protein (9CI) (CA INDEX
NAME)
SQL 585
MF Unspecified
CI MAN

REFERENCE 1: 142:458903

L7 ANSWER 3 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **841330-10-7** REGISTRY
CN Cyclin-dependent kinase modulator-regulated protein (human clone
WO2005012875-SEQID-752) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 752: PN: WO2005012875 SEQID: 752 claimed protein
SQL 609
MF Unspecified
CI MAN

REFERENCE 1: 142:214836

L7 ANSWER 4 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **774620-03-0** REGISTRY
CN 13: PN: WO2004090550 SEQID: 13 unclaimed protein (9CI) (CA INDEX
NAME)
SQL 51
MF Unspecified
CI MAN

REFERENCE 1: 141:348152

L7 ANSWER 5 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **735863-68-0** REGISTRY
CN 15: PN: WO2004065621 SEQID: 501 unclaimed sequence (9CI) (CA INDEX
NAME)
SQL 690
MF Unspecified
CI MAN

09/846328

REFERENCE 1: 141:167846

L7 ANSWER 6 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **735863-67-9** REGISTRY
CN 14: PN: WO2004065621 SEQID: 500 unclaimed sequence (9CI) (CA INDEX NAME)
SQL 585
MF Unspecified
CI MAN

REFERENCE 1: 141:167846

L7 ANSWER 7 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **688832-62-4** REGISTRY
CN Immune response-regulated protein (human clone WO2004039956-SEQID-1974) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1991: PN: WO2004039956 SEQID: 1974 claimed protein
SQL 609
MF Unspecified
CI MAN

REFERENCE 1: 140:405466

L7 ANSWER 8 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **674869-10-4** REGISTRY
CN Protein DITHP (diagnostic and therapeutic protein) (human Incyte clone 957625.PT327p) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5247: PN: WO2004023973 SEQID: 5247 claimed protein
SQL 544
MF Unspecified
CI MAN

REFERENCE 1: 140:282451

L7 ANSWER 9 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **674869-09-1** REGISTRY
CN Protein DITHP (diagnostic and therapeutic protein) (human Incyte clone 957625.PT320p) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5246: PN: WO2004023973 SEQID: 5246 claimed protein
SQL 571
MF Unspecified
CI MAN

REFERENCE 1: 140:282451

L7 ANSWER 10 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **674869-08-0** REGISTRY
CN Protein DITHP (diagnostic and therapeutic protein) (human Incyte clone 957625.PT314p) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5245: PN: WO2004023973 SEQID: 5245 claimed protein
SQL 573
MF Unspecified
CI MAN

REFERENCE 1: 140:282451

Searcher : Shears 571-272-2528

L7 ANSWER 11 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **674869-07-9** REGISTRY
CN Protein DITHP (diagnostic and therapeutic protein) (human Incyte clone 957625.PT312p) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5244: PN: WO2004023973 SEQID: 5244 claimed protein
SQL 573
MF Unspecified
CI MAN

REFERENCE 1: 140:282451

L7 ANSWER 12 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **641663-89-0** REGISTRY
CN Protein (human liver C3A cell Incyte clone 088957CD1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 977: PN: US6673549 SEQID: 977 claimed protein
SQL 609
MF Unspecified
CI MAN

REFERENCE 1: 140:71531

L7 ANSWER 13 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612102-19-9** REGISTRY
CN Protein (human heart clone GenBank gi:178345 mitochondria-associated) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 55: PN: WO03087768 SEQID: 55 claimed protein
SQL 604
MF Unspecified
CI MAN

REFERENCE 1: 139:333132

L7 ANSWER 14 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **612101-68-5** REGISTRY
CN Protein (human heart clone GenBank gi:28590 mitochondria-associated) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: WO03087768 SEQID: 2 claimed protein
SQL 609
MF Unspecified
CI MAN

REFERENCE 1: 139:333132

L7 ANSWER 15 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **606155-61-7** REGISTRY
CN 1: PN: US20030180820 SEQID: 1 unclaimed protein (9CI) (CA INDEX NAME)
SQL 585
MF Unspecified
CI .MAN

REFERENCE 1: 139:273225

L7 ANSWER 16 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

09/846328

RN 597590-54-0 REGISTRY
CN 75: PN: WO03074005 SEQID: 501 unclaimed sequence (9CI) (CA INDEX NAME)
SQL 690
MF Unspecified
CI MAN

REFERENCE 1: 139:265740

L7 ANSWER 17 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 597590-53-9 REGISTRY
CN 74: PN: WO03074005 SEQID: 500 unclaimed sequence (9CI) (CA INDEX NAME)
SQL 585
MF Unspecified
CI MAN

REFERENCE 1: 139:265740

L7 ANSWER 18 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 536784-18-6 REGISTRY
CN Liver disease-associated protein (human C3A cell Incyte clone 4087621) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 370: PN: US20030108871 SEQID: 370 claimed protein
SQL 609
MF Unspecified
CI MAN

REFERENCE 1: 139:18402

L7 ANSWER 19 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 487511-25-1 REGISTRY
CN Synthetic mature HSA (synthetic construct) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2826: PN: US20040009481 TABLE: 1 claimed protein
CN GenBank CAA01260
CN GenBank CAA01260 (Translated from: GenBank A16010)
SQL 585
MF Unspecified
CI MAN

REFERENCE 1: 140:194432

L7 ANSWER 20 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 487505-60-2 REGISTRY
CN Protein (human 585-amino acid) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: US20040009481 TABLE: 1 claimed protein
CN GenBank CAA03737
CN GenBank CAA03737 (Translated from: GenBank A63633)
SQL 585
MF Unspecified
CI MAN

REFERENCE 1: 140:123703

L7 ANSWER 21 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 479953-99-6 REGISTRY

Searcher : Shears 571-272-2528

09/846328

CN Serum albumin (human gene HSA) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 30: PN: WO2005005668 PAGE: 125 claimed protein

CN GenBank AAN17825

CN GenBank AAN17825 (Translated from: GenBank AF542069)

SQL 609

MF Unspecified

CI MAN

REFERENCE 1: 142:152638

L7 ANSWER 22 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 479944-61-1 REGISTRY

CN Similar to serum albumin precursor (human clone MGC:32581 IMAGE:4714468) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 38: PN: WO2005005668 PAGE: 125 claimed protein

CN ALB protein (human clone MGC:32581 IMAGE:4714468)

CN GenBank AAH35969

CN GenBank AAH35969 (Translated from: GenBank BC035969)

SQL 396

MF Unspecified

CI MAN

REFERENCE 1: 142:152638

REFERENCE 2: 142:18196

REFERENCE 3: 138:131969

L7 ANSWER 23 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 474451-20-2 REGISTRY

CN L-Phenylalanine, L-arginyl-L- α -aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L- α -glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L- α -aspartyl-L-leucylglycyl-L- α -glutamyl-L- α -glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-L-leucyl-L-isoleucyl-L-alanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 25: PN: US20020160420 PAGE: 22 unclaimed sequence

SQL 28

MF C147 H230 N42 O41

REFERENCE 1: 137:348834

L7 ANSWER 24 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN

RN 474451-19-9 REGISTRY

CN L-Isoleucine, L-arginyl-L- α -aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L- α -glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L- α -aspartyl-L-leucylglycyl-L- α -glutamyl-L- α -glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-L-leucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 24: PN: US20020160420 PAGE: 22 unclaimed sequence

SQL 26

MF C135 H216 N40 O39

REFERENCE 1: 137:348834

09/846328

L7 ANSWER 25 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **473546-58-6** REGISTRY
CN L-Alanine, L- α -aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L- α -glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L- α -aspartyl-L-leucylglycyl-L- α -glutamyl-L- α -glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-L-leucyl-L-isoleucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020161177 PAGE: 7 claimed protein
SQL 26
MF C132 H209 N37 O39

REFERENCE 1: 137:334906

L7 ANSWER 26 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **445052-67-5** REGISTRY
CN Albumin (human gene ALB) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1089: PN: US20040009481 TABLE: 1 claimed protein
CN 1815: PN: WO2004038376 TABLE: 5 unclaimed protein
CN 2836: PN: WO02059377 TABLE: 1A claimed sequence
CN GenBank AAA98797
CN GenBank AAA98797 (Translated from: GenBank M12523)
SQL 609
MF Unspecified
CI MAN

REFERENCE 1: 141:308582

REFERENCE 2: 140:402911

REFERENCE 3: 140:194432

REFERENCE 4: 137:152024

L7 ANSWER 27 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **444951-52-4** REGISTRY
CN Alloalbumin Venezia (human gene ALB) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1088: PN: US20040009481 TABLE: 1 claimed protein
CN 1814: PN: WO2004038376 TABLE: 5 unclaimed protein
CN 2835: PN: WO02059377 TABLE: 1A claimed sequence
CN GenBank AAA98798
CN GenBank AAA98798 (Translated from: GenBank M12523)
SQL 604
MF Unspecified
CI MAN

REFERENCE 1: 141:308582

REFERENCE 2: 140:402911

REFERENCE 3: 140:194432

REFERENCE 4: 137:152024

L7 ANSWER 28 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN **402550-28-1** REGISTRY
CN 44: PN: WO0216412 SEQID: 445 unclaimed protein (9CI) (CA INDEX NAME)

Searcher : Shears 571-272-2528

09/846328

SOL 585
MF Unspecified
CI MAN

REFERENCE 1: 136:215418

L7 ANSWER 29 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 402550-23-6 REGISTRY
CN 379: PN: WO0216411 SEQID: 445 unclaimed protein (9CI) (CA INDEX NAME)
SQL 585
MF Unspecified
CI MAN

REFERENCE 1: 136:215417

L7 ANSWER 30 OF 30 REGISTRY COPYRIGHT 2005 ACS on STN
RN 98420-25-8 REGISTRY
CN L-Leucine, L- α -aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L- α -glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L- α -aspartyl-L-leucylglycyl-L- α -glutamyl-L- α -glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: US20020160531 PAGE: 7 claimed protein
SQL 24
MF C123 H193 N35 O37

REFERENCE 1: 137:333522

REFERENCE 2: 109:147409

REFERENCE 3: 104:2400

FILE 'MEDLINE' ENTERED AT 14:38:58 ON 23 AUG 2005

FILE 'BIOSIS' ENTERED AT 14:38:58 ON 23 AUG 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 14:38:58 ON 23 AUG 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

L8 3 L7

=> dup rem 18
PROCESSING COMPLETED FOR L8
L9 3 DUP REM L8 (0 DUPLICATES REMOVED)

L9 ANSWER 1 OF 3 MEDLINE on STN
ACCESSION NUMBER: 2003033346 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12540467
TITLE: Feasibility study of NeoMend, a percutaneous arterial closure device that uses a nonthrombogenic bioadhesive.
AUTHOR: Funovics M A; Wolf F; Philipp M O; Kee S; Tichy B;
Dirisamer A; Rand T; Lammer J
CORPORATE SOURCE: Department of Angiography and Interventional Radiology,
Universitätsklinik für Radiodiagnostik, AKH Wien,
Währinger Gürtel 18-20, A-1090 Vienna, Austria.
SOURCE: AJR. American journal of roentgenology, (2003 Feb) 180
(2) 533-8.

Searcher : Shears 571-272-2528

PUB. COUNTRY: United States
 DOCUMENT TYPE: (CLINICAL TRIAL)
 (CLINICAL TRIAL, PHASE I)
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
 ENTRY MONTH: 200302
 ENTRY DATE: Entered STN: 20030124
 Last Updated on STN: 20030227
 Entered Medline: 20030226

AB OBJECTIVE: The aim of this prospective single-center phase I feasibility study was to investigate the safety and efficacy of a novel vascular sealing device, the NeoMend Arterial Closure Device, that uses a bioadhesive after percutaneous endovascular procedures. SUBJECTS AND METHODS: In 26 consecutive patients, the sealing device was deployed at the femoral artery access site immediately after a catheterization procedure using a 6-French (1.91-mm) sheath. Patients were followed up at 24 hr with Doppler sonography of the treated femoral artery puncture site, and at 1 week and 1 month by a telephone interview. RESULTS: Successful hemostasis was achieved with the NeoMend Arterial Closure Device in 21 (88%) of 24 patients. One major complication required surgery: formation of puncture site hematoma and pseudoaneurysm 3 days after the intervention after successful primary hemostasis. Two device failures required crossover to manual compression, which was done without further complications. The mean time to hemostasis was 7.0 +/- 4.5 min. Mean time to ambulation was 6.0 hr. At follow-up, the patients did not report any puncture-site-related complaints. Doppler sonography of the puncture sites revealed three insignificant hematomas of less than 20 mL and patent common femoral vessels without stenoses. CONCLUSION: The NeoMend Arterial Closure Device appears to achieve rapid hemostasis with the potential of early ambulation after arterial punctures with a 6-French sheath. The device is an alternative in situations in which suture- or collagen-mediated devices show high complication rates.

L9 ANSWER 2 OF 3 MEDLINE on STN
 ACCESSION NUMBER: 86084732 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 3841092
 TITLE: Isolation, purification and ^{13}C - and ^1H -n.m.r. assignments of peptide [1-24] of human serum albumin.
 AUTHOR: Laussac J P; Sarkar B
 SOURCE: International journal of peptide and protein research, (1985 Oct) 26 (4) 425-38.
 Journal code: 0330420. ISSN: 0367-8377.
 PUB. COUNTRY: Denmark
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198602
 ENTRY DATE: Entered STN: 19900321
 Last Updated on STN: 19900321
 Entered Medline: 19860213

AB Isolation, purification and 360 MHz ^1H - and ^{13}C -n.m.r. spectra of the residue corresponding to the NH₂-terminal peptide fragment [1-24] of human serum albumin are reported. The various resonances have been assigned to individual amino acid residues and their spatial microenvironment has been determined in a straightforward manner on the basis of (i) pH dependent chemical shifts; (ii) combined use of

multiple and selective proton-decoupled ^1H - and ^{13}C -n.m.r. spectra; (iii) the characteristic pK values exhibited by protons adjacent to sites of ionization in the molecule; and (iv) comparison of the spectra with the NH₂-terminal tripeptide segment of human albumin. The pK values of different ionizable groups all fall in the normal range expected for each titrating sites and support a model of peptide-fragment [1-24] in which there is no special structure-forming strong associations. These results are in agreement with those obtained by CD spectroscopy.

L9 ANSWER 3 OF 3 MEDLINE on STN
 ACCESSION NUMBER: 84280848 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 6547847
 TITLE: Characterization of the copper(II)- and nickel(II)-transport site of human serum albumin. Studies of copper(II) and nickel(II) binding to peptide 1-24 of human serum albumin by ^{13}C and ^1H NMR spectroscopy.
 AUTHOR: Laussac J P; Sarkar B
 SOURCE: Biochemistry, (1984 Jun 5) 23 (12) 2832-8.
 Journal code: 0370623. ISSN: 0006-2960.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198409
 ENTRY DATE: Entered STN: 19900320
 Last Updated on STN: 19970203
 Entered Medline: 19840926

AB As a basis for understanding the role of albumin in the transport of metal ions, detailed investigations have been carried out to elucidate the structure of Ni(II)- and Cu(II)-binding site of the peptide residue corresponding to the NH₂-terminal peptide fragment 1-24 of human serum albumin by ^1H and ^{13}C NMR spectroscopy. These studies have been conducted in aqueous medium at different pH values and at different ligand/metal ratios. The results show the following: (i) Diamagnetic Ni(II) complex and paramagnetic Cu(II) complex are in slow exchange NMR time scale. (ii) Titration results of Ni(II)-bound form of peptide 1-24 show the presence of a 1:1 complex in the wide pH range (6.0-11.0), and the same stoichiometry is proposed for Cu(II) as well. (iii) Analysis of the spectra suggests that both Ni(II) and Cu(II) have one specific binding site at the NH₂-terminal tripeptide segment (Asp-Ala-His...) involving the Asp alpha-NH₂, His N(1) imidazole, two deprotonated peptide nitrogens (Ala NH and His NH), and the Asp COO- group. (iv) Complexation of Ni(II) and Cu(II) causes conformational change near the metal-binding site of the polypeptide chain, but there is no other binding group involved besides those in the first three residues.

FILE 'HOME' ENTERED AT 14:39:09 ON 23 AUG 2005

09/846328

=> d his ful

(FILE 'HOME' ENTERED AT 14:30:15 ON 23 AUG 2005)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:31:09 ON 23 AUG 2005
L1 874 SEA ABB=ON PLU=ON DAHKSEVAHRFKDLGEENFKALVL/SQSP

FILE 'CAPLUS' ENTERED AT 14:32:01 ON 23 AUG 2005
L2 148 SEA ABB=ON PLU=ON L1
L3 4 SEA ABB=ON PLU=ON L2 AND (BIOMARKER OR (BIO OR BIOL?) (W)M
ARKER)
L4 20 SEA ABB=ON PLU=ON L2 AND (INDICAT? OR DETERM? OR DETECT?
OR DET## OR SCREEN? OR DIAGNOS?) (S) (DISEAS? OR DISORDER)
L5 21 SEA ABB=ON PLU=ON L3 OR L4
D 1-21 .BEVSTR
SEL HIT L5 1-21 RN

FILE 'REGISTRY' ENTERED AT 14:37:54 ON 23 AUG 2005
L6 30 SEA ABB=ON PLU=ON (444951-52-4/B1 OR 445052-67-5/B1 OR
402550-23-6/B1 OR 402550-28-1/B1 OR 473546-58-6/B1 OR
474451-19-9/B1 OR 474451-20-2/B1 OR 479944-61-1/B1 OR
479953-99-6/B1 OR 487505-60-2/B1 OR 487511-25-1/B1 OR
536784-18-6/B1 OR 597590-53-9/B1 OR 597590-54-0/B1 OR
606155-61-7/B1 OR 612101-68-5/B1 OR 612102-19-9/B1 OR
641663-89-0/B1 OR 674869-07-9/B1 OR 674869-08-0/B1 OR
674869-09-1/B1 OR 674869-10-4/B1 OR 688832-62-4/B1 OR
735863-67-9/B1 OR 735863-68-0/B1 OR 774620-03-0/B1 OR
841330-10-7/B1 OR 851737-28-5/B1 OR 851737-29-6/B1 OR
98420-25-8/B1)
D QUE
L7 30 SEA ABB=ON PLU=ON L1 AND L6
D L7 1-30 .BEVREG

FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 14:38:58 ON 23 AUG 2005
L8 3 SEA ABB=ON PLU=ON L7
L9 3 DUP REM L8 (0 DUPLICATES REMOVED)
D 1-3 IBIB ABS

FILE 'HOME' ENTERED AT 14:39:09 ON 23 AUG 2005

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2005 HIGHEST RN 861291-85-2
DICTIONARY FILE UPDATES: 22 AUG 2005 HIGHEST RN 861291-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Searcher : Shears 571-272-2528

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMI
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 23 Aug 2005 VOL 143 ISS 9
FILE LAST UPDATED: 22 Aug 2005 (20050822/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE MEDLINE

FILE LAST UPDATED: 20 AUG 2005 (20050820/UP). FILE COVERS 1950 TO DA

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP
RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

09/846328

RECORDS LAST ADDED: 17 August 2005 (20050817/ED)

FILE RELOADED: 19 October 2003.

FILE EMBASE

FILE COVERS 1974 TO 18 Aug 2005 (20050818/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.